Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.65 |
| ▸ | F12 | P00748 | 11/20 | 0.59 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | F11 | P03951 | 1/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29932268 | 0.97 | CXCR4 (0.66) | CXCR4F12KLK7KLKB1 | |
| SCHEMBL29932166 | 0.97 | CXCR4 (0.66) | CXCR4F12KLK7KLKB1 | |
| SCHEMBL29836096 | 0.96 | CXCR4 (0.68) | CXCR4F12KLKB1 | |
| SCHEMBL29932059 | 0.96 | CXCR4 (0.68) | CXCR4F12KLKB1 | |
| SCHEMBL29932154 | 0.96 | CXCR4 (0.68) | CXCR4F12KLKB1 | |
| SCHEMBL29932269 | 0.96 | CXCR4 (0.68) | CXCR4F12KLKB1 | |
| SCHEMBL29932248 | 0.96 | CXCR4 (0.68) | CXCR4F12KLK7KLKB1 | |
| SCHEMBL29932260 | 0.96 | CXCR4 (0.68) | CXCR4F12KLK7KLKB1 | |
| SCHEMBL29932187 | 0.93 | CXCR4 (0.64) | CXCR4F12 | |
| SCHEMBL29932113 | 0.91 | CXCR4 (0.60) | CXCR4F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648293-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-05-16 | — | — | US | disclosed |
| US-11642393-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-05-09 | — | — | US | disclosed |
| US-11638742-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
| US-11638743-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
| US-20230104343-A1 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | BIOLINERX LTD. (IL) | 2023-04-06 | — | — | US | disclosed |
| US-11612638-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-03-28 | — | — | US | disclosed |
| US-11607444-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-03-21 | — | — | US | disclosed |
| US-11596666-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-03-07 | — | — | US | disclosed |
| US-11590200-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-02-28 | — | — | US | disclosed |
| US-11559562-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-01-24 | — | — | US | disclosed |
| US-11554159-B2 | Compositions and methods for treating cancer | Blokine Therapeutics Ltd. (IL) | 2023-01-17 | — | — | US | disclosed |
| US-11534478-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2022-12-27 | — | — | US | disclosed |
| US-20220288155-A1 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | BIOLINERX LTD. (IL) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638742-B2 | Compositions and methods for treating cancer | CD274, PDCD1, PDCD1LG2 | CXCR4 10/4885F12 4223/4885KLK7 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.